Cannovum AG has participated in the consultation process of the German government for the legalization of cannabis for Adult-use.
Berlin, 04th July 2022. Cannovum AG has participated in the consultation process of the German government for the legalization of cannabis for Adult-use. The consultation process marks the start of the legislative process for legalization, with the draft bill to be presented at the end of this year.
The consultations initially focused on obtaining a comprehensive overview of the various topics that are particularly essential for the responsible implementation of legalization. To this end, issues relating to security of supply and supply chains as well as consumer, youth and health protection were examined in depth in five sessions. In addition to the federal ministries involved, other participants included state governments, local authorities, scientists and representatives of social interest groups.
Pia Marten, CEO of Cannovum AG participated in the International Expert Hearing on other countries' experiences with the regulated and controlled distribution of cannabis to adults. Presentations included the legalization models of Luxembourg, South Africa, Canada and the Netherlands. The keynote presentations were complemented by a panel discussion of national and international experts. Cannovum AG was represented as a member of the Cannabis Industry Association(BvCW). Finally, an open panel discussion took place in camera, with Pia Marten addressing value chains and sustainability. The BvCW attended three sessions of the consultation process in an advisory capacity.
"We are pleased that the federal government recognizes the social reality and we are thus experiencing a historic moment. Never before has the legalization of cannabis as a stimulant been discussed so seriously. The meetings of the consultation process have shown that we are no longer talking about WHETHER to legalize cannabis, but HOW. The experiences of other countries have shown us that legalization is in the interest of consumers and society and I am very positive that we will find a good way for Germany," says Pia Marten,CEO of Cannovum AG.
With its high-quality cannabis, Cannovum will also contribute to a responsible legalization in the recreational market in order to minimize the undoubted dangers of cannabis consumption.
Cannovum AG is the first listed German fully-licensed medical cannabis company. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.
Linda Rasch, Head of Communications, Cannovum AG Phone+49 30 3982 163 62
The Management Board of Cannovum AG today resolved to increase the share capital.
Cannovum Medical Education (CME) is a free, comprehensive virtual continuing education platform for medical cannabis, in which the medical-therapeutic basics of medical cannabis are scientifically prepared.
From now on, delivery to every pharmacy throughout Germany will take place directly on the next working day if the order is placed by 12:30 pm.